Analyst Douglas Loe of Echelon Wealth Partners has lowered his rating from “Speculative Buy” to “Hold” for drug developer ProMetic Life Sciences … [Read more...] about Take a pass on ProMetic Life Sciences, says Echelon Wealth
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Theratech’s new results don’t move the needle for Mackie Research
Following a fresh set of results from Theratechnologies (Theratechnologies Stock Quote, Chart TSX:TH) Mackie Research Capital analyst André Uddin has … [Read more...] about Theratech’s new results don’t move the needle for Mackie Research
Acerus Pharmaceutical has a huge upside, Mackie Research says
After completing a new financing round, specialty pharma company Acerus Pharmaceuticals (Acerus Pharmaceuticals Stock Quote. Chart TSX:ASP) retains … [Read more...] about Acerus Pharmaceutical has a huge upside, Mackie Research says
Promis Neurosciences placed under review at Mackie Research
In a client update on Thursday, Mackie Research analyst André Uddin has changed his rating for biotech company Promis Neurosciences (Promis … [Read more...] about Promis Neurosciences placed under review at Mackie Research
Tetra Bio-Pharma is a junior to own in 2019, Paradigm Capital says
Following the release of the company's 2018 fiscal results, Paradigm Capital analyst Rahul Sarugaser is still betting on Tetra Bio-Pharma (Tetra … [Read more...] about Tetra Bio-Pharma is a junior to own in 2019, Paradigm Capital says
Buy IMV for a double and then some, Echelon Wealth says
Echelon Wealth Partners analyst Doug Loe is holding steady on his estimation of IMV (IMV Stock Quote, Chart TSX:IMV) after the clinical stage biotech … [Read more...] about Buy IMV for a double and then some, Echelon Wealth says
Sell Promis Neurosciences, Mackie Research says
An Alzheimer’s drug trial failure has caused Mackie Research analyst André Uddin to downgrade his rating for Promis Neurosciences (Promis … [Read more...] about Sell Promis Neurosciences, Mackie Research says
IMV has a 49 per cent upside, Mackie Research says
Biotech company IMV (IMV Stock Quote, Chart TSX:IMV) got a target reduction Friday from Mackie Research Capital’s André Uddin, who reminds that the … [Read more...] about IMV has a 49 per cent upside, Mackie Research says
Cipher Pharma has a huge upside, says Echelon Wealth
Look for Cipher Pharmaceuticals (Cipher Pharmaceuticals Stock Quote, Chart TSX:CPH) to break out of its slump in 2019, says Doug Loe of Echelon Wealth … [Read more...] about Cipher Pharma has a huge upside, says Echelon Wealth
Aurinia Pharma has a 56 per cent upside, Mackie Research says
Mackie Research analyst André Uddin is bullish on Canadian drug development company Aurinia Pharmaceuticals (Aurinia Pharmaceuticals Stock Quote, … [Read more...] about Aurinia Pharma has a 56 per cent upside, Mackie Research says
